Cancer Drug Parity Act of 2021

United States117th CongressHR-4385House of Representatives
Updated: Jul 9, 2021

Summary

Cancer Drug Parity Act of 20 21 This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-3080: Cancer Drug Parity Act of 2021

Introduced in Senate

  1. Introduced in House

  2. Referred to the House Committee on Education and Labor.

    House of Representatives

All available records shown.